Allspring Global Investments Boosts Stake in Regeneron Pharmaceuticals

Hedge fund increases holdings in biotech company by 40% in Q4 2025

Apr. 4, 2026 at 7:25am

Got story updates? Submit your updates here. ›

A cinematic close-up of intricate, polished metal gears and machinery in shades of silver, steel, and gunmetal grey, conceptually representing the complex financial infrastructure and institutional investment power behind Regeneron Pharmaceuticals.Allspring Global Investments' increased stake in Regeneron Pharmaceuticals signals continued confidence in the biotech firm's growth and innovation.Tarrytown Today

Allspring Global Investments Holdings LLC grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 40.1% in the fourth quarter of 2025, according to a recent SEC filing. The fund now owns 37,559 shares of the biopharmaceutical company's stock, valued at $29,157,000.

Why it matters

Regeneron is a leading biotech firm known for its innovative drug discovery technologies and pipeline of biologic therapies. This investment by a major institutional investor signals continued confidence in the company's growth prospects and future performance.

The details

Allspring Global Investments purchased an additional 10,759 shares of Regeneron in Q4 2025, bringing its total holdings to 37,559 shares. This represents a 40.1% increase in the fund's position compared to the prior quarter. Regeneron's stock has seen strong performance over the past year, driven by the success of its key drug products and ongoing research and development efforts.

  • Allspring Global Investments filed its Q4 2025 13F report on April 4, 2026.
  • The filing discloses Allspring's increased stake in Regeneron as of the end of 2025.

The players

Allspring Global Investments Holdings LLC

A major institutional investment management firm that oversees over $600 billion in client assets.

Regeneron Pharmaceuticals, Inc.

A leading American biotechnology company focused on discovering, developing, manufacturing, and commercializing new medicines for serious medical conditions.

Got photos? Submit your photos here. ›

The takeaway

Allspring Global Investments' increased stake in Regeneron Pharmaceuticals underscores the biotech firm's strong market position and growth potential in the eyes of major institutional investors. This move reflects ongoing confidence in Regeneron's innovative drug pipeline and ability to deliver long-term shareholder value.